Submit your requirements and our technical
team will help.
| English Name | Research Code | Highest Development Stage | Company | Indication | Clinical Trial |
|---|---|---|---|---|---|
| Bintrafusp alfa | M-7824; GSK-4045154; MSB-0011359C | Phase 3 Clinical | Merck Serono | Anus Neoplasms; Biliary Tract Neoplasms; Brain metastases; Breast Neoplasms; Carcinoma; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Carcinoma, Small Cell; Carcinoma, Transitional Cell; Cholangiocarcinoma; Colonic Neoplasms; Colorectal Neoplasms; Esthesioneuroblastoma, Olfactory; Gallbladder Neoplasms; Ganglioglioma; Head and Neck Neoplasms; Hematologic Neoplasms; Intestinal Neoplasms; Lung Neoplasms; Lymphoma; Melanoma; Metastatic breast cancer; Microsatellite Instability; Nasopharyngeal Carcinoma; Neoplasm Metastasis; Neoplasms; Neoplasms, Germ Cell and Embryonal; Nose Neoplasms; Oropharyngeal Neoplasms; Pancreatic Neoplasms; Papillomavirus Infections; Penile Neoplasms; Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant; Rectal Neoplasms; Respiratory papillomatosis; Sarcoma; Sarcoma, Kaposi; Skin Melanoma; Small Cell Lung Carcinoma; Solid tumours; Squamous Cell Carcinoma of Head and Neck; Stomach Neoplasms; Thymic epithelial tumor; Thymoma; Thymus Neoplasms; Triple Negative Breast Neop | Details |
| Erfonrilimab | KN-046 | Phase 3 Clinical | Jiangsu Alphamab Biopharmaceuticals Co Ltd | Biliary Tract Neoplasms; Breast Neoplasms; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Carcinoma, Pancreatic Ductal; Colonic Neoplasms; Colorectal Neoplasms; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Gastrointestinal Neoplasms; Lymphoma; Neuroendocrine Tumors; Pancreatic Neoplasms; Solid tumours; Stomach Neoplasms; Thymoma; Thymus Neoplasms; Triple Negative Breast Neoplasms | Details |
| HLX-43 | HLX-43; HLX43 | Phase 3 Clinical | Shanghai Henlius Biotech Inc | Breast Neoplasms; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Carcinoma, Pancreatic Ductal; Colonic Neoplasms; Colorectal Neoplasms; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Gastroesophageal Junction Neoplasms; Head and Neck Neoplasms; Liver Neoplasms; Lung Neoplasms; Nasopharyngeal Carcinoma; Ovarian Neoplasms; Small Cell Lung Carcinoma; Solid tumours; Squamous Cell Carcinoma of Head and Neck; Stomach Neoplasms; Triple Negative Breast Neoplasms; Uterine Cervical Neoplasms | Details |
| LB-1410 | LB-1410 | Phase 3 Clinical | L&L Biopharma Co Ltd | Lymphoma; Neoplasms; Solid tumours; Uterine Cervical Neoplasms | Details |
| SGN-PDL1V | SGN-PDL1V; PF-08046054 | Phase 3 Clinical | Seagen Inc | Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Endometrial Neoplasms; Esophageal Squamous Cell Carcinoma; Pancreatic Neoplasms; Solid tumours; Squamous Cell Carcinoma of Head and Neck; Stomach Neoplasms; Triple Negative Breast Neoplasms | Details |
| SHS-006(Nanjing Sanhome Pharmaceutical) | SHS-006; SH-006; SH006 | Phase 3 Clinical | Nanjing Sanhome Pharmaceutical Co Ltd | Carcinoma, Hepatocellular; Liver Neoplasms; Solid tumours | Details |
| CA-170 | CA-170; AUPM-170 | Phase 3 Clinical | Aurigene | Carcinoma, Non-Small-Cell Lung; Neoplasms; Solid tumours | Details |
| Sotiburafusp alfa | HB0025; HB-0025 | Phase 3 Clinical | HuaBo Biopharm Co Ltd, Shanghai Huaota Biopharmaceutical Co Ltd, Zhejiang Huahai Pharmaceutical Co Ltd | Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Colorectal Neoplasms; Endometrial Neoplasms; Hematologic Neoplasms; Kidney Neoplasms; Solid tumours; Triple Negative Breast Neoplasms | Details |
| HL-301 | HL-301 | Phase 3 Clinical | Hanmi Pharmaceutical Co Ltd | Acute Bronchitis; Lung Neoplasms; Pulmonary Disease, Chronic Obstructive; Radiation Pneumonitis | Details |
| Pumitamig | PM-8002; BMS-986545; PM8002; BNT-327 | Phase 3 Clinical | Breast Neoplasms; Carcinoma, Hepatocellular; Carcinoma, Neuroendocrine; Carcinoma, Non-Small-Cell Lung; Carcinoma, Pancreatic Ductal; Carcinoma, Renal Cell; Colorectal Neoplasms; Esophageal adenocarcinoma; Gastroesophageal Junction Neoplasms; Glioblastoma; Glioma; Liver Neoplasms; Lung Neoplasms; Mesothelioma; Metastatic breast cancer; Neoplasms; Neuroendocrine Tumors; Pancreatic Neoplasms; Small Cell Lung Carcinoma; Solid tumours; Stomach Neoplasms; Triple Negative Breast Neoplasms | Details | |
| FAZ-053 | FAZ-053; LAE-005; LAE005 | Phase 2 Clinical | Novartis Pharma Ag | Chordoma; Sarcoma, Alveolar Soft Part; Solid tumours; Triple Negative Breast Neoplasms | Details |
| MAX-10181 | MAX-1; MAX-10181; MX-10181 | Phase 2 Clinical | MaxiNovel Pharmaceuticals Co Ltd | Glioblastoma; Glioma; Neoplasms; Solid tumours | Details |
| 89Zr-DFO-Atezolizumab | 89Zr-DFO-Atezolizumab | Phase 2 Clinical | University of Texas Southwestern Medical Center | Carcinoma, Renal Cell; Diagnostic agents; Lymphoma, B-Cell | Details |
| PD-L1 t-haNK cell therapy | Phase 2 Clinical | Nantkwest Inc | Esophageal Neoplasms; Glioblastoma; Head and Neck Neoplasms; Neoplasm Metastasis; Pancreatic Neoplasms; Solid tumours; Squamous Cell Carcinoma of Head and Neck; Triple Negative Breast Neoplasms | Details | |
| RC-98 | RC-98; RC98; RC98-ADC | Phase 2 Clinical | Solid tumours; Stomach Neoplasms | Details | |
| Durvalumab/Gefitinib | Phase 2 Clinical | Medimmune | Carcinoma, Non-Small-Cell Lung | Details | |
| Vudalimab | XmAb-717; XmAb-20717; XmAb 717 | Phase 2 Clinical | Xencor Inc | Adenocarcinoma, Clear Cell; Adenoma, Acidophil; Adnexal Diseases; Astrocytoma; Biliary Tract Neoplasms; Breast Neoplasms; Carcinoma, Basal Cell; Carcinoma, Hepatocellular; Carcinoma, Neuroendocrine; Carcinoma, Non-Small-Cell Lung; Carcinoma, Ovarian Epithelial; Carcinoma, Renal Cell; Carcinoma, Squamous Cell; Carcinoma, Transitional Cell; Castration-Sensitive Prostate Neoplasms; Cholangiocarcinoma; Colonic Neoplasms; Colorectal Neoplasms; Endometrial Neoplasms; Fallopian Tube Neoplasms; Gastroesophageal Junction Neoplasms; Hodgkin Disease; Melanoma; Mesothelioma; Nasopharyngeal Carcinoma; Ovarian Neoplasms; Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant; Rectal Neoplasms; Small Cell Lung Carcinoma; Solid tumours; Squamous Cell Carcinoma of Head and Neck; Stomach Neoplasms; Thymoma; Thyroid Neoplasms; Uterine Cervical Neoplasms; Vulvar Neoplasms | Details |
| Cadapersen | RG-6084; RO-7191863 | Phase 2 Clinical | F. Hoffmann-La Roche Ltd | Hepatitis B; Hepatitis B, Chronic | Details |
| BMS-936559 | MDX-1105; BMS-936559 | Phase 2 Clinical | Bristol-Myers Squibb Company | Colonic Neoplasms; Colorectal Neoplasms; HIV Infections; Hodgkin Disease; Leukemia, Myelogenous, Chronic; Liver Neoplasms; Lymphoma, Non-Hodgkin; Melanoma; Multiple Myeloma; Neoplasms; Rectal Neoplasms; Sepsis; Shock, Septic; Small Cell Lung Carcinoma | Details |
| PD-L1/CTLA4 bispecific monoclonal antibody (Changhai Hospital) | Phase 2 Clinical | Changhai Hospital of Navy Medical University | Pancreatic Neoplasms | Details | |
| PM-8001 | 6MW3111; PM-8001 | Phase 2 Clinical | Carcinoma, Non-Small-Cell Lung; Lung Neoplasms; Neoplasms; Solid tumours | Details | |
| Betifisolimab | MSB-2311 | Phase 2 Clinical | Suzhou Transcenta Therapeutics Co Ltd | Solid tumours | Details |
| Evixapodlin | GS-4224; OX-4224 | Phase 2 Clinical | Gilead Sciences Inc | Carcinoma, Non-Small-Cell Lung; Solid tumours | Details |
| 89Zr-durvalumab | Phase 2 Clinical | Radboud University Nijmegen | Carcinoma, Non-Small-Cell Lung; Head and Neck Neoplasms | Details | |
| Danburstotug | STI-3031; STI-A1015; IMC-001 | Phase 2 Clinical | Sorrento Therapeutics Inc | Biliary Tract Neoplasms; Lymphoma; Lymphoma, Extranodal NK-T-Cell; Lymphoma, Large B-Cell, Diffuse; Lymphoma, T-Cell, Peripheral; Neoplasm Metastasis; Neoplasms; Solid tumours | Details |
| Type 1 diabetes stem cell gene therapy (Altheia Science) | Phase 2 Clinical | Altheia Science Srl | Diabetes Mellitus, Type 1 | Details | |
| Recombinant humanized PD-L1 monoclonal antibody (Taizhou Houde Aoke Technology) | LP-002 | Phase 2 Clinical | Taizhou Houde Aoke Technology Co Ltd | Carcinoma, Squamous Cell; Digestive System Neoplasms; Melanoma; Primary mediastinal B cell lymphoma; Small Cell Lung Carcinoma; Solid tumours | Details |
| AP-203 | AP-203; AP203 | Phase 2 Clinical | AP Biosciences Inc | Carcinoma, Non-Small-Cell Lung; Esophageal Squamous Cell Carcinoma; Solid tumours; Squamous Cell Carcinoma of Head and Neck | Details |
| HB-0036 | HB-0036 | Phase 2 Clinical | HuaBo Biopharm Co Ltd | Carcinoma, Non-Small-Cell Lung; Solid tumours | Details |
| SKB-103 | SKB103; SKB-103 | Phase 2 Clinical | Sichuan Kelun-Biotech Biopharmaceutical Co Ltd | Solid tumours | Details |
| [18F]AlF-NOTA-PCP2 | 18F-AlF-NOTA-PCP2 | Phase 2 Clinical | Shandong First Medical University | Carcinoma, Non-Small-Cell Lung; Esophageal Neoplasms; Glioblastoma; Squamous Cell Carcinoma of Head and Neck | Details |
| HY-05350 | HY-0005; HY-05350 | Phase 2 Clinical | Sichuan Huiyu Seacross Pharma Technology Ltd | Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Mesothelioma; Ovarian Neoplasms; Pancreatic Neoplasms; Solid tumours | Details |
| IBI-3014 | IBI3014; IBI-3014 | Phase 2 Clinical | Solid tumours | Details | |
| DB-1419 | DB-1419 | Phase 2 Clinical | Duality Biologics (Suzhou) Co Ltd | Solid tumours | Details |
| CVL006 | CVL006; B006 | Phase 2 Clinical | Convalife (Shanghai) Co Ltd | Neoplasms; Solid tumours | Details |
| SOA-101 | SOA-101; SOA101 | Phase 2 Clinical | Shine-On BioMedical Co Ltd | Brain Neoplasms; Breast Neoplasms; Lung Neoplasms; Mouth Neoplasms; Ovarian Neoplasms; Solid tumours | Details |
| JSKN-033 | JSKN033; JSKN-033; JSKN-003/Envafolimab | Phase 2 Clinical | Jiangsu Alphamab Biopharmaceuticals Co Ltd | Carcinoma, Non-Small-Cell Lung; Neoplasms; Solid tumours; Uterine Cervical Neoplasms | Details |
| SPX-303 | SPX-303 | Phase 2 Clinical | SparX Biopharmaceutical Corp | Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Colorectal Neoplasms; Gastroesophageal Junction Neoplasms; Melanoma; Solid tumours; Squamous Cell Carcinoma of Head and Neck; Stomach Neoplasms | Details |
| MAX-80391 | MAX-80391; MAX-8 | Phase 2 Clinical | MaxiNovel Pharmaceuticals Co Ltd | Solid tumours | Details |
| PRS-344 | PRS-344S095012; S-095012; S-95012; PRS-344/ONC0055; PRS-344; PRS-344/S095012 | Phase 2 Clinical | Pieris Pharmaceuticals Inc | Solid tumours | Details |
| Pacmilimab | CX-072 | Phase 2 Clinical | Cytomx Therapeutics Inc | Breast Neoplasms; Lymphoma; Melanoma; Neoplasms; Solid tumours; Triple Negative Breast Neoplasms | Details |
| BPB-101 | BPB-101 | Phase 2 Clinical | Betta Pharmaceuticals Co Ltd | Solid tumours | Details |
| LB-101 (Centessa Pharmaceuticals) | LB-101 (Centessa Pharmaceuticals); LB-101 Tetravalent PD-L1xCD47 LockBody bispecific monoclonal antibody | Phase 2 Clinical | Centessa Pharmaceuticals Plc | Solid tumours | Details |
| HK-010 | HK-010; HK010 | Phase 2 Clinical | Anhui Anke Biotechnology (Group) Co Ltd, Hefei Hankemab Biotechnology Co Ltd | Neoplasms; Solid tumours | Details |
| AB-001 (Agastiya Biotech) | AB01 (Agastiya Biotech); AB001 (Agastiya Biotech); AB-01 (Agastiya Biotech) | Phase 2 Clinical | Agastiya Biotech LLC | Neoplasms | Details |
| 6MW-3511 | 6MW-3511 | Phase 2 Clinical | Mabwell (Shanghai) Bioscience Co Ltd | Neoplasms; Solid tumours | Details |
| 18F-BMS-986229 | 18F-BMS-986229; [18F]BMS-986229 | Phase 2 Clinical | Bristol-Myers Squibb International Corp, PeptiDream Inc | Adenocarcinoma; Carcinoma, Non-Small-Cell Lung; Esophageal Neoplasms; Stomach Neoplasms | Details |
| AP-505 | AP-505; B1962; AP505 | Phase 2 Clinical | AP Biosciences Inc | Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Carcinoma, Ovarian Epithelial; Colorectal Neoplasms; Liver Neoplasms; Lung Neoplasms; Neoplasms; Small Cell Lung Carcinoma; Solid tumours; Triple Negative Breast Neoplasms; Uterine Cervical Neoplasms | Details |
| Emfizatamab | GNC-038 | Phase 2 Clinical | Sichuan Baili Pharmaceutical Co Ltd, SystImmune | Arthritis, Rheumatoid; Central Nervous System Lymphoma; Lupus Erythematosus, Systemic; Lymphoma, Extranodal NK-T-Cell; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Non-Hodgkin; Lymphoma, T-Cell; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Solid tumours | Details |
| 99mTc-NM-01 | 99mTc-NM-01 | Phase 2 Clinical | Nanomab Technology Ltd | Carcinoma, Non-Small-Cell Lung | Details |
| HB-0028 | HB-0028 | Phase 2 Clinical | HuaBo Biopharm Co Ltd, Shanghai Huaota Biopharmaceutical Co Ltd | Solid tumours; Uterine Cervical Neoplasms | Details |
| PM-1022 | PM-1022 | Phase 2 Clinical | Neoplasms | Details | |
| DR-30206 | DR-30206 | Phase 2 Clinical | Zhejiang Doer Biologics Corp | Carcinoma, Non-Small-Cell Lung; Gastrointestinal Neoplasms; Solid tumours; Squamous Cell Carcinoma of Head and Neck | Details |
| 706-3SBio | SSGJ-706; 706 anti -PD1/PD -L1 BsAb; 706 anti-PD1/PD-L1 Bispecific antibody | Phase 2 Clinical | 3sbio Inc | Carcinoma, Non-Small-Cell Lung; Carcinoma, Pancreatic Ductal; Colorectal Neoplasms; Composite Lymphoma; Digestive System Neoplasms; Esophageal Neoplasms; Lymphoma; Neoplasms; Solid tumours | Details |
| BCD-106 | BCD-106 | Phase 2 Clinical | BIOCAD JSC | Solid tumours | Details |
| BAT-7104 | BAT-7104 | Phase 2 Clinical | Bio-Thera Solutions Ltd | Neoplasms; Solid tumours | Details |
| Opamtistomig | LBL-024; LBL024 | Phase 2 Clinical | Nanjing Leadsbiolabs Co Ltd | Carcinoma, Neuroendocrine; Melanoma; Neoplasms; Ovarian Neoplasms; Solid tumours; Triple Negative Breast Neoplasms | Details |
| IBC-0966 | IBC-0966 | Phase 2 Clinical | Neoplasms | Details | |
| QLF31907 | QLF31907; QLF-31907 | Phase 2 Clinical | Qilu Pharmaceutical Co Ltd | Carcinoma, Transitional Cell; Lymphoma, Non-Hodgkin; Melanoma; Neoplasms; Solid tumours | Details |
| INCB-099280 | INCB-099280; INCB-99280 | Phase 2 Clinical | Incyte Corp Ltd | Carcinoma, Hepatocellular; Carcinoma, Merkel Cell; Carcinoma, Renal Cell; Carcinoma, Squamous Cell; Carcinoma, Transitional Cell; Colorectal Neoplasms; Esophageal Squamous Cell Carcinoma; Melanoma; Mesothelioma; Microsatellite instability-high cancer; Mismatch Repair Deficient Cancer; Nasopharyngeal Carcinoma; Neoplasms; Small Cell Lung Carcinoma; Solid tumours; Uterine Cervical Neoplasms | Details |
| FH-2001 | FH-2001 | Phase 2 Clinical | Solid tumours | Details | |
| Nebratamig | GNC-035 | Phase 2 Clinical | Sichuan Baili Pharmaceutical Co Ltd | Breast Neoplasms; Hematologic Neoplasms; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Non-Hodgkin; Metastatic breast cancer; Solid tumours | Details |
| Carrizumab | Phase 2 Clinical | Jiangsu Hengrui Medicine Co Ltd | Adenocarcinoma; Esophageal Neoplasms; Stomach Neoplasms | Details | |
| Recombinant anti-PD-L1/TGF-β bispecific antibody | Y101D; Y-101D | Phase 2 Clinical | Wuhan Yzy Biopharma Co Ltd | Carcinoma, Hepatocellular; Pancreatic Neoplasms; Solid tumours | Details |
| 6MW-3211 | 6MW3211; 6MW-3211 | Phase 2 Clinical | Mabwell (Shanghai) Bioscience Co Ltd | Carcinoma, Renal Cell; Leukemia, Myeloid, Acute; Lung Neoplasms; Lymphoma; Myelodysplastic Syndromes; Neoplasms | Details |
| Q-1802 | Q-1802 | Phase 2 Clinical | Qure Biotechnology (Shanghai) Co Ltd | Esophageal Neoplasms; Gastrointestinal Neoplasms; Solid tumours | Details |
| HLX-301 | HLX-301 | Phase 2 Clinical | Carcinoma, Non-Small-Cell Lung; Esophageal Neoplasms; Lymphoma; Neoplasm Metastasis; Neoplasms; Small Cell Lung Carcinoma; Solid tumours; Squamous Cell Carcinoma of Head and Neck | Details | |
| PD-L1 antibody combined with CTLA-4 antibody (Shanghai Zhongshan Hospital) | Phase 2 Clinical | Shanghai Zhongshan Hospital | Cholangiocarcinoma | Details | |
| Palverafusp alfa | IMM-2510; SYN-2510; AXN-2510 | Phase 2 Clinical | Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Endometrial Neoplasms; Esophageal Squamous Cell Carcinoma; Neoplasms; Sarcoma; Solid tumours; Triple Negative Breast Neoplasms | Details | |
| PM-1003 | PM1003 | Phase 2 Clinical | Solid tumours | Details | |
| PM-8003 | PM8003 | Phase 2 Clinical | Solid tumours | Details | |
| ABSK-043 | ABSK043 | Phase 2 Clinical | ABbisko Therapeutics Co Ltd | Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Carcinoma, Transitional Cell; Esophageal Neoplasms; Neoplasms; Sarcoma; Solid tumours | Details |
| Lesabelimab | BC-003; ADG-104 | Phase 2 Clinical | Adagene (Suzhou) Ltd, Baifan Biotechnology (Shanghai) Co Ltd, Dragonboat Biopharmaceutical, Guilin Sanjin Pharmaceutical Co Ltd | Carcinoma, Renal Cell; Neoplasms; Penile Neoplasms; Urinary Bladder Neoplasms | Details |
| Emdifen | Phase 1 Clinical | Chinese Academy Of Medical Sciences, Tianjin Chase Sun Pharmaceutical Co Ltd | Solid tumours | Details | |
| Chimeric antigen receptor T-cell therapy (Hunan Zhaotai Yongren Biotech) | Z-CTLs | Phase 1 Clinical | Hunan Zhaotai Yongren Biotech Co Ltd | Carcinoma, Non-Small-Cell Lung | Details |
| Lodapolimab | LY-3300054 | Phase 1 Clinical | Eli Lilly And Company | Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Microsatellite instability-high cancer; Neoplasms; Pancreatic Neoplasms; Skin Melanoma; Solid tumours; Triple Negative Breast Neoplasms | Details |
| SL-279252 | TAK-252; SL-279252 | Phase 1 Clinical | Shattuck Labs Inc, Takeda Pharmaceutical Co Ltd | Adenocarcinoma; Astrocytoma; Carcinoma, Basosquamous; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Carcinoma, Squamous Cell; Carcinoma, Transitional Cell; Esophageal Neoplasms; Gastroesophageal Junction Neoplasms; Hodgkin Disease; Lymphoma, Large B-Cell, Diffuse; Melanoma; Solid tumours; Squamous Cell Carcinoma of Head and Neck; Stomach Neoplasms | Details |
| LOR-S03 | CDX-527 | Phase 1 Clinical | Celldex Therapeutics | Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Carcinoma, Transitional Cell; Cholangiocarcinoma; Colorectal Neoplasms; Esophageal Neoplasms; Fallopian Tube Neoplasms; Head and Neck Neoplasms; Liver Neoplasms; Ovarian Neoplasms; Peritoneal Neoplasms; Solid tumours; Stomach Neoplasms | Details |
| MCLA-145 | MCLA-145 | Phase 1 Clinical | Incyte Corp, Merus Nv | Lymphoma, B-Cell; Neoplasms; Solid tumours | Details |
| INCB-086550 | INCB-086550; INCB-86550 | Phase 1 Clinical | Incyte Corp | Carcinoma; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Melanoma; Solid tumours | Details |
| Opucolimab | HLX-20 | Phase 1 Clinical | Neoplasms; Solid tumours | Details | |
| IMMH-010 | IMMH-010 | Phase 1 Clinical | Tianjin Chase Sun Pharmaceutical Co Ltd | Neoplasms; Solid tumours | Details |
| Simridarlimab | IBI-322; IBI322 | Phase 1 Clinical | Bone Marrow Neoplasms; Hematologic Neoplasms; Leukemia, Myeloid, Acute; Lymphoma; Lymphoma, T-Cell; Neoplasms; Solid tumours | Details | |
| dual anti-HER2/anti-PD-L1 CAR T-cell therapy (Sichuan University) | Phase 1 Clinical | Sichuan University | Carcinoma, Non-Small-Cell Lung; Metastatic breast cancer; Ovarian Neoplasms; Peritoneal Neoplasms; Stomach Neoplasms | Details | |
| anti-PD-L1 CSR T-cell therapy (Marino Biotechnology) | Phase 1 Clinical | Beijing Marino Biotechnology Co Ltd | Glioblastoma; Neoplasms | Details | |
| anti-PSMA/anti-PSCA CAR T-cell therapy PD-1 silent (Shanghai Unicar-Therapy Bio-medicine) | Phase 1 Clinical | Shanghai Unicar-Therapy Bio-Medicine Technology Co Ltd | Hormone-Resistant Prostate Neoplasms | Details | |
| AB-101 (Arbutus Biopharma) | AB-101 (Arbutus Biopharma) | Phase 1 Clinical | Arbutus Biopharma Corp | Hepatitis B; Hepatitis B, Chronic | Details |
| SIM-0237 | SIM-0237; SIM-237 | Phase 1 Clinical | Simcere Pharmaceutical Group Ltd | Solid tumours; Urinary Bladder Neoplasms | Details |
| LP-008 | LP-008 | Phase 1 Clinical | Lepu Biopharma Co Ltd | Solid tumours | Details |
| AN-8025 | AN-8025 | Phase 1 Clinical | Hangzhou Adlai Nortye Biopharma Co Ltd | Solid tumours | Details |
| EMB-09 | EMB-09 | Phase 1 Clinical | Shanghai Epimab Biotherapeutics, Inc | Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Colorectal Neoplasms; Endometrial Neoplasms; Hepatitis B, Chronic; Melanoma; Nasopharyngeal Carcinoma; Neoplasms; Ovarian Neoplasms; Small Cell Lung Carcinoma; Solid tumours; Squamous Cell Carcinoma of Head and Neck; Stomach Neoplasms; Triple Negative Breast Neoplasms | Details |
| CYTO-102 | CYTO-NK-102; CYTO-102; COH06 | Phase 1 Clinical | CytoImmune Therapeutics Inc | Carcinoma, Non-Small-Cell Lung; Lung Neoplasms | Details |
| TS-1905 | TS-1905; LY-01019; BA-1201 | Phase 1 Clinical | Shandong Boan Biotechnology Co Ltd | Solid tumours | Details |
| BH-3120 | BH-3120 | Phase 1 Clinical | Hanmi Pharmaceutical Co Ltd | Solid tumours | Details |
| Xirestomig | ATG-101; ATG101; YN051 | Phase 1 Clinical | The Origin Cell Technology Group Co Ltd | Hematologic Neoplasms; Lymphoma, B-Cell; Lymphoma, Non-Hodgkin; Solid tumours | Details |
| QL-301 | QL-301 | Phase 1 Clinical | Qlsf Biotherapeutics Inc | Neoplasms | Details |
| HLX-37 | HLX37; HLX-37 | Phase 1 Clinical | Shanghai Henlius Biotech Inc | Carcinoma, Non-Small-Cell Lung; Lung Neoplasms; Neoplasm Metastasis; Solid tumours; Triple Negative Breast Neoplasms | Details |
| Q-1801 | Q-1801; Q 1801 | Phase 1 Clinical | Qure Biotechnology (Shanghai) Co Ltd | Solid tumours | Details |
| PEC-QT | PEC-QT; VCTX-210 | Phase 1 Clinical | Crispr Therapeutics Ag, Viacyte Inc | Autoimmune Diseases; Diabetes Mellitus; Diabetes Mellitus, Type 1; Endocrine System Diseases; Glucose Metabolism Disorders; Immune System Diseases; Metabolic Diseases | Details |
| IMGS-001 | IMGS-001 | Phase 1 Clinical | The University Of Texas MD Anderson Cancer Center | Colorectal Neoplasms; Neoplasms; Prostatic Neoplasms; Solid tumours; Triple Negative Breast Neoplasms | Details |
| ABL-501 | ABL-501 | Phase 1 Clinical | Abl Bio Inc | Solid tumours | Details |
| CTX-8371 | CTX-8371 | Phase 1 Clinical | Compass Therapeutics LLC | Carcinoma, Non-Small-Cell Lung; Hodgkin Disease; Melanoma; Solid tumours; Squamous Cell Carcinoma of Head and Neck; Triple Negative Breast Neoplasms | Details |
| IBC-Ab002 | IBC-Ab002 | Phase 1 Clinical | ImmunoBrain Checkpoint Inc | Alzheimer Disease | Details |
| Pd-1-pik | Pd-1-pik | Phase 1 Clinical | Huashan Hospital Affiliated To Fudan University | Glioblastoma | Details |
| Reozalimab | IBI-318; LY-3434172; LY3434172 | Phase 1 Clinical | Eli Lilly And Company | Carcinoma, Hepatocellular; Carcinoma, Squamous Cell; Lymphoma, Extranodal NK-T-Cell; Neoplasms; Small Cell Lung Carcinoma | Details |
| VSV-02 | VSV-02 | Phase 1 Clinical | Joint Biosciences Ltd | Breast Neoplasms; Lung Neoplasms; Melanoma; Neoplasms; Solid tumours | Details |
| 188Re-NM-01 | 188Re-NM-01 | Phase 1 Clinical | Nanomab Technology Ltd | Lung Neoplasms | Details |
| 68Ga-NOTA-WL12 | Phase 1 Clinical | Beijing Cancer Hospital | Carcinoma, Non-Small-Cell Lung | Details | |
| [18F]DK222 | [18F]DK-222; [18F]DK222 | Phase 1 Clinical | Sidney Kimmel Comprehensive Cancer Center | Carcinoma; Carcinoma, Non-Small-Cell Lung | Details |
| JSKN-027 | JSKN027; JSKN-027 | Phase 1 Clinical | Alphamab Oncology | Neoplasms; Solid tumours | Details |
| PF-08046037 | PF-08046037; SGN-PDL1iT | Phase 1 Clinical | Pfizer Inc | Carcinoma, Non-Small-Cell Lung; Carcinoma, Pancreatic Ductal; Melanoma; Neoplasms; Squamous Cell Carcinoma of Head and Neck | Details |
| BMS-986238 | BMS-986238 | Phase 1 Clinical | Bristol-Myers Squibb Belgium Sa | Lymphoma; Solid tumours | Details |
| Naptumomab estafenatox/Durvalumab | NTX-352 | Phase 1 Clinical | Neotx Therapeutics Ltd | Solid tumours | Details |
| DCR-PDL1 | DCR-PDL1 | Phase 1 Clinical | Dicerna Pharmaceuticals Inc | Solid tumours | Details |
| XB-628 | XB628 | Phase 1 Clinical | Exelixis Inc | Neoplasms; Solid tumours | Details |
| BHP-01 | BHP-01; BHP01; α-PD-L1/4-1BB DLL3 CAR-T | Phase 1 Clinical | Chengdu Brilliant Pharmaceutical Co Ltd | Small Cell Lung Carcinoma | Details |
| JSKN-022 | JSKN022; JSKN-022 | Phase 1 Clinical | Alphamab Oncology | Neoplasms; Solid tumours | Details |
| LW-347 | LW-347 | Phase 1 Clinical | Shanghai Longwood Biopharmaceuticals Co Ltd | Neoplasms | Details |
| A-337 (Klus Pharma) | A337 (Klus Pharma); A-337 (Klus Pharma) | Phase 1 Clinical | Klus Pharma Inc | Neoplasms | Details |
| PMI-06 | PMI-06; PMI06; 18F-DK222; [18F]DK-222 | Phase 1 Clinical | Precision Molecular Inc | Carcinoma, Non-Small-Cell Lung | Details |
| YL-222 | YL222; YL-222 | Phase 1 Clinical | MediLink Therapeutics Co Ltd | Solid tumours | Details |
| BAT-7205 | BAT7205; BAT-7205 | Phase 1 Clinical | Bio-Thera Solutions Ltd | Neoplasm Metastasis; Solid tumours | Details |
| SM-2275 | SM-2275; SM2275 | Phase 1 Clinical | Zhuhai StarMab BioMed Technology Ltd | Solid tumours | Details |
| ND-021 | ND-021; NM21-1480; CS-2006; CS2006 | Phase 1 Clinical | Cstone Pharmaceuticals, Numab Therapeutics Ag | Carcinoma, Non-Small-Cell Lung; Carcinoma, Ovarian Epithelial; Carcinoma, Squamous Cell; Colorectal Neoplasms; Fallopian Tube Neoplasms; Neoplasms; Peritoneal Neoplasms; Solid tumours; Squamous Cell Carcinoma of Head and Neck; Triple Negative Breast Neoplasms | Details |
| MAX-001 | MAX-001; MAX001 | Phase 1 Clinical | Inflamax Pharmaceuticals (Guangzhou) Co Ltd | Solid tumours | Details |
| KM602 | KM602; KM-602; XZP-KM602 | Phase 1 Clinical | Xuanzhu (Shijiazhuang) Biotechnology Co Ltd | Solid tumours | Details |
| B-901 | B-901; B901 | Phase 1 Clinical | FutureGen Biopharm (Beijing) Co Ltd | Solid tumours | Details |
| Recombinant anti-PD-L1/TGF-β bifunctional fusion protein | Phase 1 Clinical | Hualan Genetic Engineering (Henan) Co Ltd | Solid tumours | Details | |
| AUR-106 | AUR-106 | Phase 1 Clinical | Aurigene Discovery Technologies Ltd | Carcinoma, Non-Small-Cell Lung; Carcinoma, Transitional Cell; Colonic Neoplasms; Esophageal Neoplasms; Kidney Neoplasms; Neoplasms; Stomach Neoplasms | Details |
| 177Lu-RAD204 | 177Lu-anti-PD-L1 sdAb; RAD-204; 177Lu-RAD204 | Phase 1 Clinical | Radiopharm Theranostics Ltd | Carcinoma, Non-Small-Cell Lung; Endometrial Neoplasms; Mismatch Repair Deficient Cancer; Skin Melanoma; Small Cell Lung Carcinoma; Squamous Cell Carcinoma of Head and Neck; Triple Negative Breast Neoplasms | Details |
| RAD-203 | RAD-203 | Phase 1 Clinical | Radiopharm Theranostics Ltd | Carcinoma, Non-Small-Cell Lung | Details |
| Dual-targeting VEGFR1 and PD-L1 CAR-T cells Therapy (Sichuan University) | Phase 1 Clinical | Sichuan University | Ascites; Serositis | Details | |
| Ori-Bs-001 | Ori-Bs-001 | Phase 1 Clinical | OriCell Therapeutics Co Ltd | Solid tumours | Details |
| HBM-9027 | HBM-9027; HBM9027 | Phase 1 Clinical | Harbour Biomed | Neoplasms; Solid tumours | Details |
| HS-10386 | HS-10386 | Phase 1 Clinical | Jiangsu Hansoh Pharmaceutical Group Co Ltd, Shanghai Hansoh Biomedical Co Ltd | Solid tumours | Details |
| QL-415 | QL-415 | Phase 1 Clinical | Qlsf Biotherapeutics Inc | Neoplasms | Details |
| ASC-61 | ASC-61 | Phase 1 Clinical | Ascletis Pharma Inc | Neoplasms; Solid tumours | Details |
| BPI-371153 | BPI-371153 | Phase 1 Clinical | Betta Pharmaceuticals Co Ltd | Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Lymphoma; Solid tumours | Details |
| CS-23546 | CS-23546; CS23546 | Phase 1 Clinical | Shenzhen Chipscreen Biosciences Co Ltd | Immune System Diseases; Neoplasms | Details |
| SG-1408 | SG-1408; SG1408 | Phase 1 Clinical | Hangzhou Shangjian Biotechnology Co Ltd | Solid tumours | Details |
| CHECKvacc | CF33-hNIS-antiPDL1 | Phase 1 Clinical | City Of Hope National Medical Center, Imugene Ltd | Breast Neoplasms; Metastatic breast cancer; Triple Negative Breast Neoplasms | Details |
| Gallium [68Ga] Natan recombinant PD-L1 single domain antibody | SNA-002; 68Ga-NOTA-SNA002 | Phase 1 Clinical | Smartnuclide Biopharma | Contrast agents; Neoplasms; Solid tumours | Details |
| SHS-009 | SHS-009; SH009; SH-009 | Phase 1 Clinical | Nanjing Sanhome Pharmaceutical Co Ltd | Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Esophageal Neoplasms; Liver Neoplasms; Neoplasms; Solid tumours; Squamous Cell Carcinoma of Head and Neck; Stomach Neoplasms | Details |
| CN-202 | CN-202 | Phase 1 Clinical | Curon Biopharmaceutical Ltd | Hematologic Neoplasms; Solid tumours | Details |
| Recombinant oncolytic type II herpes simplex virus (Binhui Biopharmaceutical) | BS-006; oHSV2-BiTEs; oHSV2CD3-PD-L1 | Phase 1 Clinical | Wuhan Binhui Biotechnology Co Ltd | Melanoma; Neoplasms; Solid tumours; Uterine Cervical Neoplasms | Details |
| FS222 mAb² (F-star Therapeutics) | FS-222 | Phase 1 Clinical | F-star Beta Ltd | Neoplasm Metastasis; Neoplasms; Solid tumours | Details |
| IMM-2520 | IMM-2520 | Phase 1 Clinical | Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Colorectal Neoplasms; Small Cell Lung Carcinoma; Solid tumours; Squamous Cell Carcinoma of Head and Neck | Details | |
| TT-00420/Atezolizumab | Phase 1 Clinical | TransThera Sciences (Nanjing) Inc | Gastrointestinal Neoplasms | Details | |
| PF-07257876 | Phase 1 Clinical | Pfizer Inc | Carcinoma, Non-Small-Cell Lung; Ovarian Neoplasms; Squamous Cell Carcinoma of Head and Neck | Details | |
| AN-4005 | AN-4005 | Phase 1 Clinical | Hangzhou Adlai Nortye Biopharma Co Ltd | Lymphoma; Neoplasms; Solid tumours | Details |
| BR-102 | BR102 | Phase 1 Clinical | Zhejiang BioRay Biopharmaceuticals Co Ltd | Neoplasms; Solid tumours | Details |
| TST-005 | TST-005; TST005 | Phase 1 Clinical | Suzhou Transcenta Therapeutics Co Ltd | Neoplasms; Papillomavirus Infections; Solid tumours | Details |
| GS-19 | GT-90008; GS-19; GS-19-PLB-1C | Phase 1 Clinical | Gensun Biopharma Inc | Solid tumours | Details |
| Ragistomig | ABL-503; TJ-L14B/ABL503; ABL503; TJ-L14B | Phase 1 Clinical | I-Mab Biopharma Co Ltd | Solid tumours | Details |
| CCX-559 | CCX-559 | Phase 1 Clinical | Chemocentryx Inc | Neoplasms; Solid tumours | Details |
| Dual-targeting HER2 and PD-L1 CAR-T Cell Therapy (Sichuan University) | Phase 1 Clinical | Sichuan University | Peritoneal Neoplasms; Pleural Effusion, Malignant | Details | |
| QLS31901 | QLS-31901; QLS31901 | Phase 1 Clinical | Qilu Pharmaceutical Co Ltd | Neoplasms | Details |
| IMM2505 | IMM2505; IMM-2505 | Phase 1 Clinical | SunHo (China) BioPharmaceutical Co Ltd | Solid tumours | Details |
| SKB-337 | SKB337; A-337; SKB-337 | Phase 1 Clinical | Sichuan Kelun-Biotech Biopharmaceutical Co Ltd | Solid tumours | Details |
| GNC-039 | GNC-039 | Phase 1 Clinical | Sichuan Baili Pharmaceutical Co Ltd | Glioma; Hematologic Neoplasms; Neoplasm Metastasis; Solid tumours | Details |
| IBI-323(Innovent Biologics) | IBI-323 | Phase 1 Clinical | Neoplasms; Solid tumours | Details | |
| BJ-005 | BJ-005 | Phase 1 Clinical | Boji Biomedical Technology (Hangzhou) Co Ltd | Lymphoma; Solid tumours | Details |
| Garivulimab | BGB-A333 | Phase 1 Clinical | BeOne Medicines Ltd | Neoplasms; Solid tumours | Details |
| Recombinant anti-PD-L1 human monoclonal antibody (Jiansu huaiyu) | Phase 1 Clinical | Jiangsu Huaiyu Pharmaceutical Co Ltd | Solid tumours | Details | |
| Durvalumab/Selumetinib sulfate | Phase 1 Clinical | Astrazeneca Plc | Neoplasms | Details | |
| 18F-BMS-986192 | BMS-986192-[18F] | Clinical | Bristol-Myers Squibb Company | Neoplasms | Details |
| 68Ga-THP-APN09 | Clinical | Beijing Cancer Hospital | Lung Neoplasms | Details | |
| [68Ga]Ga-NOTA-RW102 | Clinical | Huashan Hospital | Carcinoma, Non-Small-Cell Lung | Details | |
| 18F-WL12 | 18F-WL12; 18F-WL-12 | Clinical | Beijing Cancer Hospital | Lung Neoplasms | Details |
| 68Ga-WL12 | [68Ga]WL12; 68Ga-WL12; 68Ga-WL-12 | Clinical | Beijing Cancer Hospital | Lung Neoplasms | Details |
| CTB-1 | CTB-1 | Clinical | GTS Biotech LLC | Neoplasms | Details |
| 89Zr-KN035(Wuxi No. 4 People's Hospital) | Clinical | Wuxi No. 4 People | Solid tumours | Details |
| English Name | Research Code | Highest Development Stage | Company | First Brand Name | First Approved Country | First Indication | First Approved Company | First Approved Date | Indication | Clinical Trial |
|---|---|---|---|---|---|---|---|---|---|---|
| Socazolimab | ZKAB001; STI-A1014; STIA-1014; ZKAB-001; STI-1014 | Approved | Sorrento Therapeutics Inc, Zhaoke (Guangzhou) Oncology Pharmaceutical Ltd | 善克钰 | Mainland China | Uterine Cervical Neoplasms | Zhaoke (Guangzhou) Oncology Pharmaceutical Ltd | 2023-12-19 | Bile Duct Neoplasms; Biliary Tract Neoplasms; Carcinoma, Transitional Cell; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Melanoma; Osteosarcoma; Small Cell Lung Carcinoma; Uterine Cervical Neoplasms | Details |
| Envafolimab | KN-035; ASC-22 | Approved | 3d Medicines (Sichuan) Co Ltd, Suzhou Alphamab Co Ltd | ENWEIDA, 恩维达 | Mainland China | Mismatch Repair Deficient Cancer; Microsatellite instability-high cancer | 3d Medicines (Sichuan) Co Ltd | 2021-11-25 | Bile Duct Neoplasms; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Colonic Neoplasms; Colorectal Neoplasms; Dermatofibrosarcoma; Endometrial Neoplasms; Esophageal Squamous Cell Carcinoma; Gastroesophageal Junction Neoplasms; Hepatitis B, Chronic; HIV Infections; Liver Neoplasms; Microsatellite instability-high cancer; Mismatch Repair Deficient Cancer; Sarcoma; Sepsis; Shock, Septic; Solid tumours; Stomach Neoplasms | Details |
| Retlirafusp alfa | SHR-1701 | Approved | Jiangsu Hengrui Medicine Co Ltd | 艾泽利 | Mainland China | Stomach Neoplasms; Esophageal Neoplasms | Suzhou Suncadia Biopharmaceuticals Co Ltd | 2026-01-07 | Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Cholangiocarcinoma; Colorectal Neoplasms; Esophageal Neoplasms; Gastroesophageal Junction Neoplasms; Hodgkin Disease; Lung Neoplasms; Lymphangioma, Cystic; Nasopharyngeal Carcinoma; Neoplasms; Pancreatic Neoplasms; Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant; Rectal Neoplasms; Solid tumours; Squamous Cell Carcinoma of Head and Neck; Stomach Neoplasms; Uterine Cervical Neoplasms | Details |
| Atezolizumab | RG-7446-42; RO-5541267; 52CMI0WC3Y (UNII code); RG-7446; MPDL-3280A | Approved | Genentech Inc | 泰圣奇, Tecentriq, 泰善可 | United States | Carcinoma, Non-Small-Cell Lung | Genentech Inc | 2016-05-18 | Anus Neoplasms; Bile Duct Neoplasms; Biliary Tract Neoplasms; Breast Neoplasms; Carcinoma; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Carcinoma, Squamous Cell; Carcinoma, Transitional Cell; Chondrosarcoma; Colorectal Neoplasms; Endometrial Neoplasms; Fallopian Tube Neoplasms; Gastroesophageal Junction Neoplasms; Gastrointestinal Neoplasms; Genital Neoplasms, Female; Glioblastoma; Glioma; Head and Neck Neoplasms; Hematologic Neoplasms; Hodgkin Disease; Idiopathic Pulmonary Fibrosis; Kidney Diseases; Kidney Neoplasms; Laryngeal Neoplasms; Leukemia, Lymphocytic, Chronic, B-Cell; Liposarcoma; Liposarcoma, Myxoid; Liver Neoplasms; Lung Neoplasms; Lymphoma; Lymphoma, Follicular; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Non-Hodgkin; Lymphoma, T-Cell, Cutaneous; Lymphoproliferative Disorders; Melanoma; Metastatic breast cancer; Multiple Myeloma; Mycosis Fungoides; Myelodysplastic Syndromes; Neoplasms; Neoplasms, Unknown Primary; Neuroendocrine Tumors; Oropharyngeal Neoplasms; | Details |
| Avelumab | PF-06834635; MSB-0010718C | Approved | Merck Serono | Bavencio | United States | Carcinoma, Merkel Cell | Emd Serono Inc | 2017-03-23 | Adenocarcinoma; Carcinoma; Carcinoma, Adenoid Cystic; Carcinoma, Hepatocellular; Carcinoma, Merkel Cell; Carcinoma, Neuroendocrine; Carcinoma, Non-Small-Cell Lung; Carcinoma, Ovarian Epithelial; Carcinoma, Pancreatic Ductal; Carcinoma, Renal Cell; Carcinoma, Transitional Cell; Colonic Neoplasms; Colorectal Neoplasms; Endometrial Neoplasms; Esophageal Squamous Cell Carcinoma; Fallopian Tube Neoplasms; Glioblastoma; Gonadal Disorders; Hodgkin Disease; Leukemia, Lymphocytic, Chronic, B-Cell; Leukemia, Myeloid, Acute; Lymphoma; Lymphoma, B-Cell; Lymphoma, Extranodal NK-T-Cell; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Large-Cell, Anaplastic; Lymphoma, T-Cell; Lymphoma, T-Cell, Peripheral; Meningeal Neoplasms; Meningioma; Mesothelioma; Microsatellite Instability; Microsatellite instability-high cancer; Multiple Myeloma; Mycosis Fungoides; Nasopharyngeal Neoplasms; Neoplasm Metastasis; Neoplasms; Neoplasms, Germ Cell and Embryonal; Neuroendocrine Tumors; Osteosarcoma; Ovarian Neoplasms; Pancreatic Neoplasms; Papil | Details |
| Tagitanlimab | KL-A167; A-167; HBM-9167 | Approved | Sichuan Kelun-Biotech Biopharmaceutical Co Ltd | 科泰莱 | Mainland China | Nasopharyngeal Carcinoma | Sichuan Kelun-Biotech Biopharmaceutical Co Ltd | 2024-12-25 | Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Esophageal Neoplasms; Hodgkin Disease; Lymphoma; Lymphoma, B-Cell; Lymphoma, Extranodal NK-T-Cell; Nasopharyngeal Carcinoma; Small Cell Lung Carcinoma; Solid tumours; Stomach Neoplasms; Triple Negative Breast Neoplasms | Details |
| Adebrelimab | SHR-1316; HTI-1088; HTI-1316 | Approved | Atridia Pty Ltd, Jiangsu Hengrui Medicine Co Ltd | 艾瑞利 | Mainland China | Small Cell Lung Carcinoma | Shanghai Suncadia Medicine Co Ltd | 2023-02-28 | Adenocarcinoma; Breast Neoplasms; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Carcinoma, Transitional Cell; Cholangiocarcinoma; Colorectal Neoplasms; Esophageal Squamous Cell Carcinoma; Gastroesophageal Junction Neoplasms; Lung Neoplasms; Nasopharyngeal Carcinoma; Nasopharyngeal Neoplasms; Neoplasm Metastasis; Neoplasms; Ovarian Diseases; Ovarian Neoplasms; Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant; Rectal Neoplasms; Small Cell Lung Carcinoma; Solid tumours; Squamous Cell Carcinoma of Head and Neck; Stomach Neoplasms; Triple Negative Breast Neoplasms; Urinary Bladder Neoplasms; Uterine Cervical Neoplasms | Details |
| Durvalumab | 28X28X9-OKV (UNII code); MEDI-4736 | Approved | Medimmune Llc | Imfinzi, 英飞凡 | United States | Carcinoma, Non-Small-Cell Lung | Astrazeneca Uk Ltd | 2017-05-01 | Adenocarcinoma; Adenocarcinoma of Lung; Bile Duct Neoplasms; Biliary Tract Neoplasms; Breast Neoplasms; Carcinoma; Carcinoma, Endometrioid; Carcinoma, Hepatocellular; Carcinoma, Merkel Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Ovarian Epithelial; Carcinoma, Pancreatic Ductal; Carcinoma, Renal Cell; Carcinoma, Squamous Cell; Carcinoma, Transitional Cell; Cholangiocarcinoma; Colorectal Neoplasms; Endometrial Neoplasms; Esophageal adenocarcinoma; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Fallopian Tube Neoplasms; Gallbladder Neoplasms; Gastroesophageal Junction Neoplasms; Glioblastoma; Head and Neck Neoplasms; Hormone-Resistant Prostate Neoplasms; Hydronephrosis; Kidney Neoplasms; Laryngeal Diseases; Laryngopharyngitis; Leukemia, Lymphocytic, Chronic, B-Cell; Leukemia, Myeloid, Acute; Liver Neoplasms; Lung Neoplasms; Lymphoma; Lymphoma, B-Cell; Lymphoma, Follicular; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Non-Hodgkin; Lymphoma, T-Cell; Lymphoma, T-Cell, Cutaneous; Lymphoma, T-Cell, Peri | Details |
| Cosibelimab | TG-1501; CK-301 | Approved | Dana-Farber Cancer Institute | UNLOXCY, UNLOXCIT, Unloxcyt | United States | Carcinoma, Squamous Cell | Checkpoint Therapeutics Inc | 2024-12-13 | Carcinoma, Merkel Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Carcinoma, Small Cell; Carcinoma, Squamous Cell; Carcinoma, Transitional Cell; Endometrial Neoplasms; Head and Neck Neoplasms; Hodgkin Disease; Lung Neoplasms; Lymphoma; Lymphoma, Non-Hodgkin; Melanoma | Details |
| Sugemalimab | CS-1001; WBP-3155 | Approved | Cstone Pharmaceuticals (Suzhou) Co Ltd | 择捷美, Cejemly, ZEJIEMEI | Mainland China | Carcinoma, Non-Small-Cell Lung | Cstone Pharmaceuticals (Suzhou) Co Ltd | 2021-12-20 | Adenocarcinoma; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Colorectal Neoplasms; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Gastroesophageal Junction Neoplasms; Head and Neck Neoplasms; Hodgkin Disease; Lymphoma; Lymphoma, Extranodal NK-T-Cell; Lymphoma, T-Cell; Melanoma; Neoplasms; Ovarian Neoplasms; Pancreatic Neoplasms; Prostatic Neoplasms; Small Cell Lung Carcinoma; Solid tumours; Stomach Neoplasms; Triple Negative Breast Neoplasms; Urinary Bladder Neoplasms | Details |
| Atezolizumab/Hyaluronidase | Approved | Genentech Inc | TECENTRIQ HYBREZA | United States | Sarcoma, Alveolar Soft Part; Melanoma; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Small Cell Lung Carcinoma | Genentech Inc | 2024-09-12 | Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Melanoma; Sarcoma, Alveolar Soft Part; Small Cell Lung Carcinoma | Details | |
| Benmelstobart | CBT-502; APL-502; TQ-B2450; TQB2450; TQB-2450 | Approved | Apollomics Inc | 安得卫 | Mainland China | Small Cell Lung Carcinoma | Sino Biopharmaceutical Ltd | 2024-04-30 | Adenocarcinoma; Bile Duct Neoplasms; Biliary Tract Neoplasms; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Carcinoma, Ovarian Epithelial; Carcinoma, Renal Cell; Carcinoma, Squamous Cell; Cholangiocarcinoma; Digestive System Diseases; Digestive System Neoplasms; Endometrial Neoplasms; Esophageal Diseases; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Fallopian Tube Neoplasms; Gastrointestinal Diseases; Gastrointestinal Neoplasms; Genital Neoplasms, Female; Hepatitis B, Chronic; Hodgkin Disease; Liver Neoplasms; Lung Neoplasms; Lymphoma; Lymphoma, B-Cell; Lymphoma, Extranodal NK-T-Cell; Melanoma; Nasopharyngeal Carcinoma; Neoplasms; Neoplasms, Squamous Cell; Ovarian Neoplasms; Peritoneal Neoplasms; Primary mediastinal B cell lymphoma; Sarcoma; Small Cell Lung Carcinoma; Solid tumours; Squamous Cell Carcinoma of Head and Neck; Stomach Neoplasms; Triple Negative Breast Neoplasms; Uterine Cervical Neoplasms | Details |




